Cullinan Oncology Inc.

13.39+0.0700+0.53%Vol 788.55K1Y Perf -48.99%
Jun 24th, 2022 16:00 DELAYED
BID12.00 ASK14.20
Open13.34 Previous Close13.32
Pre-Market- After-Market13.39
 - -  - -%
Target Price
34.00 
Analyst Rating
Strong Buy 1.17
Potential %
153.92 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     61.98
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
26.45 
Earnings Rating
Market Cap599.63M 
Earnings Date
9th Aug 2022
Alpha-0.07 Standard Deviation0.13
Beta0.17 

Today's Price Range

12.6713.56

52W Range

7.3030.33

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
9.75%
1 Month
20.96%
3 Months
16.64%
6 Months
-19.82%
1 Year
-48.99%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CGEM13.390.07000.53
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.61-0.2755.74
Q04 2021-0.47-0.74-57.45
Q03 2021-0.42-0.404.76
Q02 2021-0.42-0.3614.29
Q01 20210.070.00-100.00
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Aug 2022
Estimated EPS Next Report5.47
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume788.55K
Shares Outstanding44.78K
Shares Float24.08M
Trades Count6.80K
Dollar Volume10.52M
Avg. Volume548.05K
Avg. Weekly Volume610.21K
Avg. Monthly Volume454.75K
Avg. Quarterly Volume579.19K

Cullinan Oncology Inc. (NASDAQ: CGEM) stock closed at 13.39 per share at the end of the most recent trading day (a 0.53% change compared to the prior day closing price) with a volume of 788.55K shares and market capitalization of 599.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 26 people. Cullinan Oncology Inc. CEO is Owen Hughes.

The one-year performance of Cullinan Oncology Inc. stock is -48.99%, while year-to-date (YTD) performance is -13.22%. CGEM stock has a five-year performance of %. Its 52-week range is between 7.3 and 30.325, which gives CGEM stock a 52-week price range ratio of 26.45%

Cullinan Oncology Inc. currently has a PE ratio of -6.80, a price-to-book (PB) ratio of 1.30, a price-to-sale (PS) ratio of 26.37, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -16.92%, a ROC of -17.58% and a ROE of -17.52%. The company’s profit margin is -%, its EBITDA margin is -358.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cullinan Oncology Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $5.47 for the next earnings report. Cullinan Oncology Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Cullinan Oncology Inc. is Strong Buy (1.17), with a target price of $34, which is +153.92% compared to the current price. The earnings rating for Cullinan Oncology Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cullinan Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cullinan Oncology Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.27, ATR14 : 0.97, CCI20 : 110.04, Chaikin Money Flow : 0.19, MACD : 0.49, Money Flow Index : 74.15, ROC : 1.90, RSI : 61.05, STOCH (14,3) : 88.10, STOCH RSI : 1.00, UO : 58.65, Williams %R : -11.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cullinan Oncology Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.17
Strong Buy
1.17
Strong Buy
1.17

Cullinan Oncology Inc.

Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

CEO: Owen Hughes

Telephone: +1 617 410-4650

Address: One Main Street, Cambridge 02142, MA, US

Number of employees: 26

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

47%53%

Bearish Bullish

55%45%

Bearish Bullish

50%50%

News

Stocktwits